High flow oxygen therapy in obese hospitalised patients: effects on carbon dioxide levels in the blood.

Not Applicable

Completed

• Conditions: Hypercapnia as a consequence of oxygen therapy in obese individuals.; Respiratory - Other respiratory disorders / diseases; Diet and Nutrition - Obesity

• Registration Number: ACTRN12610000522011
• Lead Sponsor: Medical Research Institute of New Zealand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-06-24
• Last Update Posted: 14 June 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1. Current internal medicine inpatient in Wellington Hospital; 2. Age >/= 16 years; 3. Body Mass Index (BMI) > 40kg/m2.

Exclusion Criteria

1. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD); 2. Ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV1:FVC) < 0.7 (First 24 participants recruited only); 3. Patients currently receiving treatment with Continuous Positive Airway Pressure (CPAP) ventilation or Non-Invasive Positive Pressure Ventilation (NIPPV); 4. Patients currently requiring >2L/minute of oxygen therapy following titration to the recommended target saturation range of 88-92% (First 24 participants recruited only); 5. Patients with baseline PtCO2 of >65mmHg; 6. Current diagnosis of disease causing restriction to chest wall expansion, other than obesity i.e. neuromuscular disease or chest wall dysfunction; 7. Administration of respiratory suppressant medications, including opiate analgesia and benzodiazepines within 24 hours (First 24 participants recruited only); 8. Patients with unstable angina or recent myocardial infarction.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in PtCO2 from baseline. PtCO2 and oxygen saturation (SpO2) are assessed via a combined SpO2/PtCO2 non-invasive monitor (SENTEC (SenTec AG, Switzerland)). <br><br>[PtCO2 levels will be recorded at baseline and at the following times from onset of the intervention: 10 mins, 20 mins, 30 mins, 40 mins, 50 mins and 60 mins.]

Secondary Outcome Measures

Name	Time	Method
Proportion of subjects who have a change in PtCO2 from baseline of greater than or equal to 4mmHg.[This will be assessed from the recorded data taken from each subject at baseline, 10 mins, 20 mins, 30 mins, 40 mins, 50 mins and 60 mins.];Rate of change of PtCO2.[This will be assessed from the recorded data taken from each subject at baseline, 10 mins, 20 mins, 30 mins, 40 mins, 50 mins and 60 mins of intervention. ];Change in Respiratory Rate from baseline. Assessed by investigator count. [Taken from each subject at baseline, 10 mins, 20 mins, 30 mins, 40 mins, 50 mins and 60 mins of intervention. ];Change in Heart Rate from baseline. Assessed by SENTEC. [Taken from each subject at baseline, 10 mins, 20 mins, 30 mins, 40 mins, 50 mins and 60 mins of intervention. ];Change in Oxygen Saturation from baseline. Assessed by SENTEC. [Taken from each subject at baseline, 10 mins, 20 mins, 30 mins, 40 mins, 50 mins and 60 mins of intervention.]